About the Company
entrada therapeutics is building the leading intracellular biologics company to transform the treatment of devastating diseases. entrada was co-founded in 2016 by 5am ventures, a leading life sciences venture capital firm.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
140
Exchange
NASDAQ
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $TRDA News
Entrada Therapeutics Inc (TRDA) Reports Solid Financial Position and Advancements in Clinical Trials
Entrada Therapeutics reported a robust cash position of $352 million, a significant increase from the previous year's $188.7 ...
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular ...
Entrada Therapeutics: Buy Rating on Strong Financials and Promising Clinical Pipeline
Ram Selvaraju has given his Buy rating due to a combination of factors related to Entrada Therapeutics Inc’s solid financial position and promising clinical developments. Entrada concluded the fiscal ...
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Just Slashed This Year's Estimates
The analysts covering Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) delivered a dose of negativity to shareholders ...
Around $5M Bet On This Communication Services Stock? Check Out These 4 Stocks Insiders Are Buying
Don’t forget to check out our premarket coverage here Check This Out: Jim Cramer Likes Amazon More Than This E-Commerce Platform, Calls Chipotle 'The King' Entrada Therapeutics NewsMORE Related Stocks ...
Nkarta announces pricing of stock offering to raise $240.1M
Nkarta (NASDAQ:NKTX) announces the pricing of an underwritten offering of 21.01 million shares of its common stock for $10.00 per share and pre-funded warrants to purchase 3 million shares of common ...
Entrada Therapeutics, Inc.: Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Cash runway extended through the second quarter of 2026 - - $352 million in cash, cash equivalents and marketable securities as of December 31, 2023 - - Completed dosing for third cohort of Phase 1 ...
Loading the latest forecasts...